Zobrazeno 1 - 10
of 140
pro vyhledávání: ''
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
Supplemental Digital Content is available in the text.
Characterization of host immune cell parameters before and during immunotherapy is expected to identify predictive biomarkers for clinical outcome. We prospectively monitored blood immune ce
Characterization of host immune cell parameters before and during immunotherapy is expected to identify predictive biomarkers for clinical outcome. We prospectively monitored blood immune ce
Autor:
Jonathan D. Schoenfeld, Donald P. Lawrence, Alistair E. W. Johnson, F.S. Hodi, Patrick A. Ott, Elizabeth I. Buchbinder, Rizwan Haq, Ryan J. Sullivan, Peter Bowling, Justine V. Cohen, Michael Manos, Girish S. Naik, Ayal A. Aizer
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 44(8)
Long-term survival outcomes among melanoma patients with brain metastases treated with immune checkpoint inhibitors are limited. In this retrospective study at 2 centers, metastatic melanoma patients with radiographic evidence of brain metastases who
Autor:
Shugeng Gao, Xuemin Xue, Qing Fang, Wenbin Li, Liankui Han, Changyuan Guo, Lei Guo, Jianming Ying, Peng Song
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
The effect of chemotherapy on programmed cell death-ligand 1 (PD-L1) expression has been previously studied in lung cancer, while the results remain controversial. The aim of this study was to investigate the variation of PD-L1 expression after neoad
Autor:
Anna M. Szpurka, Sandaruwan Geeganage, Johanna C. Bendell, Johan Wallin, Shadia I. Jalal, Sylvie Rottey, Karim A. Benhadji, Hans Prenen, Leena Gandhi, Thompson N. Doman, Violeta Regnier Galvao, Nuria Kotecki, Subha Suriyapperuma, Meng Xia, Abhijoy Saha, P. Vuagnat, Xiaojian Xu, Bert H. O'Neil
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997)
LY3381916 is an orally available, highly selective, potent inhibitor of indoleamine 2,3-dioxygenase 1. This study explored the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of LY3381916 monotherapy and in combinatio
Autor:
Joshua Arnold, Barliz Waissengrin, Eliya Shachar, Michal Laufer-Perl, Ido Wolf, Ofer Merimsky, Yaron Arbel, Zach Rozenbaum, Yonatan Moshkovits, Ravit Geva, Shira Peleg Hasson, Yan Topilsky, Ayelet Sivan, Ilan Merdler, Sivan Shamai
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 44(5)
The widespread use of immune checkpoint inhibitors (ICI) has become a mainstay of care for a variety of malignancies. However, these therapies portend a range of adverse effects, including a potentially fatal form of cardiotoxicity which to date has
Autor:
Michael Erdmann, Oana D Persa, Cornelia Mauch, Carola Berking, Albert Rübben, Kerstin Schatton, M. Schlaak, Theresa Steeb
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 44(6)
Immune checkpoint inhibitors (ICIs) have tremendously changed the therapeutic landscape of melanoma since they are associated with a durable response, allowing for intentional discontinuation of therapy after complete or partial remission. However, a
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
Premelanosome protein (PMEL) is crucial for the formation of melanosomal fibrils through the transition from stage I to stage II melanosomes. It was used as a target antigen in some adoptive T-cell therapy of melanoma. The correlation of PMEL to prog
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 44(4)
This is a 2-center, retrospective study which aimed to evaluate the effect of baseline corticosteroid use on immunotherapy efficacy in patients with advanced melanoma. We included all patients with advanced unresectable and metastatic melanoma on sin
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 44(4)
Pembrolizumab is an anti-programmed cell death protein 1 immune checkpoint inhibitor with a dosing schedule of 200 mg 3 weekly (q3w). Dose of 400 mg 6 weekly (q6w) was approved based on simulation of dose/exposure relationships and predicted no diffe
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 44(1)
This retrospective study aimed to investigate the safety profile of continuing or rechallenging patients with advanced cancer who developed grade≥2 immune-related adverse events (irAEs) on immunotherapy-based regimens. Our study had 25, 20, and 40